# A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

> **NCT07307274** · PHASE1 · RECRUITING · sponsor: **Syntis Bio** · enrollment: 64 (estimated)

## Conditions studied

- Healthy
- Overweight and Obese Adults

## Interventions

- **DRUG:** SYNT101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07307274
- **Lead sponsor:** Syntis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2026-10
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307274, "A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07307274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*